Medicare Quviviq Prior Authorization: A Guide for Providers

Understanding Quviviq Coverage Under Medicare

Quviviq (daridorexant) is a dual orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. As a prescription medication, its coverage under Medicare primarily falls under Medicare Part D plans, which are administered by private insurers. These plans establish their own formularies, which may include specific prior authorization criteria, step therapy requirements, or quantity limits for medications like Quviviq.

Prior Authorization Pathways: Original Medicare vs. Medicare Advantage

The approach to prior authorization for Quviviq differs significantly between Original Medicare (Medicare Fee-for-Service) and Medicare Advantage (Part C) plans. Original Medicare has a more limited scope for prior authorization, typically focusing on specific medical services or durable medical equipment rather than most outpatient prescription drugs. However, Medicare Advantage plans, operated by private contractors, often have expanded prior authorization requirements for medications, including Part D drugs, aligning with their utilization management strategies.

Medicare Prior Authorization Submission Channels

• **Medicare Part D Pharmacy PA:** For Quviviq, prior authorization requests are typically routed through the specific Medicare Part D plan's Pharmacy Benefit Manager (PBM) or directly to the plan, following their CMS-approved formularies and step-therapy protocols.
• **Traditional Medicare Medical (Part A and B):** While less common for prescription drugs, where Traditional Medicare requires PA for specific services (e.g., certain outpatient procedures, DME), submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. MACs include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

Accessing Utilization Management Policies for Quviviq

For medical services that may have a prior authorization requirement under Original Medicare, providers reference National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) published by the responsible MAC for each jurisdiction. For Quviviq under Part D, policies are found within each plan's specific formulary and utilization management criteria, which are accessible via the plan's provider portal or PBM resources. Accurate policy identification is critical for successful prior authorization.

Klivira's Role in Medicare Quviviq Prior Authorization Automation

Klivira streamlines the prior authorization process for Quviviq across diverse Medicare landscapes. For Medicare Advantage and Part D plans, Klivira automates the submission of requests to payer portals and PBMs, applying plan-specific criteria. For the limited instances where Original Medicare prior authorization applies, Klivira's MAC-aware routing ensures submissions adhere to per-jurisdiction requirements and NCD/LCD-aware policy logic, reducing manual effort and improving turnaround times.

Key Considerations for Medicare Quviviq PA Denials and Appeals

Denials for Quviviq under Medicare Part D plans often stem from non-adherence to formulary requirements, failure to meet step-therapy criteria, or insufficient documentation of medical necessity. Providers should be prepared to submit comprehensive clinical notes supporting the diagnosis of insomnia and the medical necessity of Quviviq. Appeal pathways are clearly defined by each Medicare Part D plan, typically involving multiple levels of review, starting with a redetermination request.